<DOC>
	<DOCNO>NCT00392431</DOCNO>
	<brief_summary>Our hypothesis episodic amiodarone treatment ( i.e . amiodarone treatment 1 month prior 1 month cardioversion ) associate low morbidity high quality life compare continuous prophylactic amiodarone treatment atrial fibrillation still effectively suppress . The latter mean end study permanent atrial fibrillation prevent comparable percentage patient ( 70 % ) treatment strategy . However , accomplish cost high number electrical cardioversions ( 2-3 ) episodic treatment group compare continuous treatment group .</brief_summary>
	<brief_title>Continuous Versus Episodic Amiodarone Treatment Prevention Permanent Atrial Fibrillation</brief_title>
	<detailed_description>Primary objective To determine difference adverse event rate patient persistent atrial fibrillation randomize episodic amiodarone treatment ( EAT ) strategy patient randomize continuous amiodarone treatment ( CAT ) strategy , atrial fibrillation still effectively suppress . Adverse event relate : 1. amiodarone use 2. atrial fibrillation underlie heart disease . Secondary objective To determine difference quality life patient persistent atrial fibrillation randomize EAT strategy patient randomize CAT strategy .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Inclusion criterion : 1 . Symptomatic persistent atrial fibrillation least 48 hour 1 year ( present episode ) . 2 . Older 18 year age . 3 . Ventricular rate AF &gt; 75 beat per minute , document restECG without rate control . 4 . At least two week oral anticoagulation therapy screening . 5 . Written informed consent . Exclusion criterion : 1 . Contra indication amiodarone ( severe chronic obstructive pulmonary disease QTc &gt; 440ms ) . 2 . History relapse AF adequate amiodarone treatment ( i.e . adequate amiodarone desethylamiodarone plasma level ) . 3 . Concomitant treatment class I III antiarrhythmic drug . Amiodarone use last 3 month . 4 . Other ( non ) cardiac QT prolong drug ( possible discontinue ) . 5 . First episode persistent atrial fibrillation . 6 . More three relapse persistent atrial fibrillation necessitate electrical cardioversion last three year . 7 . Known sick sinus syndrome . 8 . History second third degree AV conduction disturbance . 9 . Intraventricular conduction disturbance ( QRS &gt; 140ms ) . 10 . Pacemaker treatment . 11 . Hemodynamically significant valvular disease . 12 . Patients heart failure symptom accord NYHA class III IV . 13 . Unstable angina pectoris . 14 . Recent myocardial infarction ( &lt; 3 month ) . 15 . PTCA , CABG , cardiac surgery major noncardiac surgery within last three month . 16 . History hyperthyroidism hypothyroidism . 17 . Serious pulmonary , hepatic , haematological , metabolic , renal , gastrointestinal , CNS psychiatric disease . 18 . Pregnant nonpregnant woman premenopausal practise acceptable method contraception . 19 . Treatment investigational agent . 20 . Presence disease likely shorten life expectancy &lt; 1 year . 21 . Any condition opinion investigator would jeopardise evaluation efficacy safety associate poor adherence protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
</DOC>